Skip to main content

Table 3 Potentials of ZnONP nanocomposites on the kidney function of EAC-challenged mice

From: Doxorubicin and folic acid-loaded zinc oxide nanoparticles-based combined anti-tumor and anti-inflammatory approach for enhanced anti-cancer therapy

Conjugates

Urea (mg/dl)

Creatinine (mg/dl)

Naive

47.67 ± 1.52

0.28 ± 0.04

EAC

54.85 ± 0.63

0.74 ± .05a

DOX

60.46 ± 2.04

0.78 ± 0.04a

ZnONPs

66.90 ± 6.14

0.79 ± 0.09a

ZnONPs/DOX

245.84 ± 21.29a,b,c

0.91 ± 0.06a,b

ZnONPs/FA

50.90 ± 1.05

0.77 ± 0.3a

ZnONPs/DOX/FA

68.15 ± 1.61

0.48 ± 0.03a,b,c

  1. Data were represented as mean ± SD (n = 10). Difference between groups was considered statistically significant at P < 0.05. Note: a,b,c Statistically significant difference as compared to the corresponding means of the naive group (a), the EAC group (b), the DOX group (c)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us